Stryker (SYK) Competitors

Abbott Laboratories (NYSE:ABT) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Is ABT or SYK more profitable?

Abbott Laboratories has a net margin of 31.95% compared to Stryker's net margin of 13.25%. Stryker's return on equity of 23.58% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	31.95%	20.74%	11.19%
Stryker	13.25%	23.58%	11.37%

Is ABT or SYK a better dividend stock?

Abbott Laboratories pays an annual dividend of $2.36 per share and has a dividend yield of 1.8%. Stryker pays an annual dividend of $3.36 per share and has a dividend yield of 0.9%. Abbott Laboratories pays out 30.8% of its earnings in the form of a dividend. Stryker pays out 43.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Abbott Laboratories has increased its dividend for 54 consecutive years and Stryker has increased its dividend for 32 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Which has stronger earnings and valuation, ABT or SYK?

Abbott Laboratories has higher revenue and earnings than Stryker. Abbott Laboratories is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$41.95B	5.41	$13.40B	$7.65	17.10
Stryker	$22.60B	6.16	$2.99B	$7.76	46.96

Does the MarketBeat Community believe in ABT or SYK?

Abbott Laboratories received 11 more outperform votes than Stryker when rated by MarketBeat users. Likewise, 69.97% of users gave Abbott Laboratories an outperform vote while only 64.57% of users gave Stryker an outperform vote.

Company	Underperform	Outperform
Abbott Laboratories	Outperform Votes 946 69.97%	Underperform Votes 406 30.03%
Stryker	Outperform Votes 935 64.57%	Underperform Votes 513 35.43%

Which has more risk and volatility, ABT or SYK?

Abbott Laboratories has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.

Does the media prefer ABT or SYK?

In the previous week, Abbott Laboratories had 17 more articles in the media than Stryker. MarketBeat recorded 65 mentions for Abbott Laboratories and 48 mentions for Stryker. Stryker's average media sentiment score of 1.48 beat Abbott Laboratories' score of 1.24 indicating that Stryker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	45 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Stryker	41 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders hold more shares of ABT or SYK?

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 0.5% of Abbott Laboratories shares are held by company insiders. Comparatively, 5.9% of Stryker shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Do analysts rate ABT or SYK?

Abbott Laboratories presently has a consensus price target of $137.94, indicating a potential upside of 5.45%. Stryker has a consensus price target of $421.90, indicating a potential upside of 15.79%. Given Stryker's higher possible upside, analysts plainly believe Stryker is more favorable than Abbott Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.84
Stryker	0 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Abbott Laboratories and Stryker tied by winning 11 of the 22 factors compared between the two stocks.